


DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)

**Derbyshire commissioning guidance for treating severe osteoporosis
(Based on NICE guidance and NOGG/ROS consensus advisory statement)**



Dosing schedule

Drug	NICE TA	Loading dose	Maintenance dose	Response measured	
Romosozumab SC	Monoclonal antibody that binds to and inhibits sclerostin	TA 791	N/A	210mg once monthly	12 months only
	Prescribing information <ul style="list-style-type: none"> • Patients should be adequately supplemented with calcium and vitamin D before and during treatment. • Romosozumab is contraindicated in patients with previous myocardial infarction or stroke. • Romosozumab should only be used if the Specialist and patient agree that the benefit outweighs the risk. • If a patient experiences a myocardial infarction or stroke during therapy, treatment with romosozumab should be discontinued. 				